Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 14/20 | 0.42 |
| ▸ | HTR3A | P46098 | 6/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.39 |
| ▸ | HTR3B | O95264 | 2/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757501 | 0.92 | CHRNA7 (0.48) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6756936 | 0.88 | CHRNA7 (0.52) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6755113 | 0.87 | CHRNA7 (0.53) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6756904 | 0.85 | CHRNA7 (0.43) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6759430 | 0.85 | CHRNA7 (0.40) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6756933 | 0.85 | CHRNA7 (0.40) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6756416 | 0.84 | CHRNA7 (0.39) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6759389 | 0.82 | CHRNA7 (0.62) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL6756927 | 0.81 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E | |
| SCHEMBL5917848 | 0.79 | CHRNA7 (0.41) | CHRNA7HTR3ACHRNB2CHRNA4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | CHRNA7 2449/4885HTR3A 4302/4885CHRNB2 3348/4885 |
| US-20040224976-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | CHRNA7 2449/4885HTR3A 4302/4885CHRNB2 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.